07/12/12Amarin shares plunge on decision to hire own sales force for Vascepa launch
14/11/11Amarin to present positive results from two phase 3 studies of anti-triglyceride drug
26/09/11Amarin submits NDA for triglyceride-lowering AMR101 drug
18/04/11Amarin shares surge on phase III results of triglyceride-lowering drug
Recent Sector News
Pressure BioSciences (OTCMKTS:PBIO) has received a vote of confidence from analyst Grant Zeng at Zacks Small Cap Research, who bumped up his 12-month price target on the company by 60%, citing strong fourth quarter and fiscal year 2013 results, improving business development strategies and a "very attractive valuation".
The quarter was a strong finish to what chief executive Richard Schumacher referred to as a year of successes for the company following four straight quarters of year-over-year revenue growth and a technological breakthrough with its core platform.
Pressure BioSciences soars on launch of ultra high pressure instrument system set to make waves in biotech industry
Pressure BioSciences said that it believes its new product will be the instrument of choice for a broad range of studies that can use the special effects of ultra-high pressure on biological samples, with the instrument capable of reaching pressure levels well beyond any automated bench-top pressure instrument on the market today.
Shares of Pressure BioSciences (OTC:PBIO) were rising on Tuesday on the back of a Seeking Alpha article that named the life sciences company among one of three chosen biotech plays the influential financial markets blog recommends investors shouldn't disregard in 2014.
Pressure BioSciences (OTC:PBIO) has closed a third tranche of its financing that has so far raised well over its initial goal, and has approved plans to extend the offering once again to bump up the total anticipated proceeds to $3.5 million.
Pressure BioSciences (OTCMKTS:PBIO), which is developing its pressure cycling technology (PCT), had its buy rating and $1.05 price target maintained Friday by Merriman Capital analyst Andrew D'Silva, who said that the life science's company recent fundraising efforts have paid off and are expected to sustain operations until the end of the fiscal year, with critical transition, rapid revenue growth and share price appreciation all in the cards.
Investors interested in Amarin recently viewed
- HealthLinx (ASX: HTX) HealthLinx will be recognised as a leader in delivering diagnostic applicat
- Pressure BioSciences (OTCQB: PBIO) .
- Consegna Group (ASX: CGP) A vehicle to the China & North Asian pharmaceutical markets
- ValiRx (AIM: VAL) Developing technologies & products in oncology therapeutics & diagnostics
- Regeneus Limited (ASX: RGS) .